ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Symptom dynamics through multiphase treatment in acute myeloid leukemia: a cross-lagged panel network analysis.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Network analysis of head and neck symptoms and fear of cancer recurrence in postoperative laryngeal cancer patients: simulation-based intervention modeling.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
objectiveTo construct symptom network for acute myeloid leukemia (AML) patients at different stages of treatment, explore the longitudinal relationships among 31 symptoms at different points, identify key causal symptoms, and determine optimal intervention time windows.
methodsAML patients admitted between July 2024 and May 2025 for chemotherapy were enrolled. Symptom incidence was assessed using the Chinese version of the Memorial Symptom Assessment Scale (MSAS-Ch) at three points: the day before chemotherapy initiation (T1), chemotherapy completion day (T2), and seven days post-chemotherapy (T3).Cross-lagged panel network (CLPN) modeling was applied to analyze longitudinal mechanisms among 31 core symptoms across three critical treatment phases.
resultsOf 275 enrolled AML patients (mean age = 56.02 ± 13.96 years), fatigue and feeling sad were the most prevalent symptoms across T1, T2, and T3. CLPN analysis identified key cross-lagged paths: difficulty swallowing (S22) → loss of appetite (S20) from T1 → T2 and weight loss (S26) → loss of appetite (S20) from T2 → T3. Predictive analysis showed feeling sad (S16) had the highest out-predictive strength in T1 → T2, while weight loss (S26) had the highest out-predictive strength in T2 → T3. Shortness of breath (S14) exhibited the highest in-predictive strength in T1 → T2, and loss of appetite (S20) had the highest in-predictive strength in T2 → T3. Centrality analysis revealed feeling sad (S16) and mental tension (S5) as the top out-strength nodes in T1 → T2, whereas mouth ulcers (S24) and weight loss (S26) were dominant in T2 → T3.
conclusionsAML symptom management should focus on the dynamic interplay of core symptoms, particularly during T2, providing targeted nutritional and psychological support guided by causal pathways to improve patient outcomes and quality of life. Future models integrating physiological data and treatment plans could enhance symptom prediction and management.
Indexed as
Identifiers
41318732What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.